Cynata Therapeutics Limited (CYP.AX)
AUD 0.2
(11.43%)
AUD 0.2
(11.43%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.96 Million | -14.28 Million | -3.29 Million | -5.16 Million | -3.38 Million | -6.75 Million |
| Net Income | -9.74 Million | -14.27 Million | -5.44 Million | -7.68 Million | -3.63 Million | -8.47 Million |
| Depreciation & Amortization | 280.73 Thousand | 279.96 Thousand | 279.96 Thousand | 279.96 Thousand | 280.73 Thousand | 279.96 Thousand |
| Deferred income taxes | - | -1.5 Million | -620.04 Thousand | -1.51 Million | -1.57 Million | -944.97 Thousand |
| Stock-based compensation | 228.46 Thousand | 326.54 Thousand | 1.03 Million | 1.53 Million | 388.23 Thousand | 904.3 Thousand |
| Change in working capital | 390.34 Thousand | -684.05 Thousand | 1 Million | 755.33 Thousand | -615.16 Thousand | 40.66 Thousand |
| Other non-cash items | -1.11 Million | 1.57 Million | 448.31 Thousand | 1.46 Million | 1.77 Million | 1.43 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | 6.72 Million | 210.12 Thousand | 18.19 Million | 10.05 Million | 1.53 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -317.82 Thousand | - | -571.95 Thousand | -406.92 Thousand | -75.51 Thousand |
| Common Stock Issuance | - | 6.72 Million | - | 17.73 Million | 8.97 Million | 1.33 Million |
| Other Financing Activities | - | 317.82 Thousand | 210.12 Thousand | 1.03 Million | 1.49 Million | 275.51 Thousand |
| Accounts receivables | 362.8 Thousand | -356.39 Thousand | 20.3 Thousand | -156.68 Thousand | 152.06 Thousand | 40.66 Thousand |
| Accounts payables | -1.11 Million | -259.97 Thousand | 951.68 Thousand | 740.93 Thousand | -780.91 Thousand | 533.61 Thousand |
| Inventory | - | - | - | - | - | -554.15 Thousand |
| Other working capital | 27.53 Thousand | -67.68 Thousand | 34.51 Thousand | 171.08 Thousand | 13.68 Thousand | 20.54 Thousand |
| Cash at beginning of period | 16.16 Million | 23.79 Million | 26.71 Million | 13.64 Million | 6.97 Million | 12.2 Million |
| Cash at end of period | 6.2 Million | 16.16 Million | 23.79 Million | 26.71 Million | 13.64 Million | 6.97 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | -1377.00 | -72.3 Thousand | 169.58 Thousand | 33 Thousand | -15.00 | 12.00 |
| Net cash flow / Change in cash | -9.96 Million | -7.63 Million | -2.91 Million | 13.06 Million | 6.67 Million | -5.22 Million |
| Free Cash Flow | -9.96 Million | -14.28 Million | -3.29 Million | -5.16 Million | -3.38 Million | -6.75 Million |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -9.74 Million | -5.2 Million | -4.54 Million | -9.1 Million | -14.27 Million | -5.17 Million |
| Depreciation & Amortization | 280.73 Thousand | 140.36 Thousand | 140.36 Thousand | 139.98 Thousand | 279.96 Thousand | 139.98 Thousand |
| Deferred income taxes | - | - | - | 7687.00 | -1.5 Million | - |
| Stock-based compensation | - | 150.39 Thousand | 78.07 Thousand | 68.74 Thousand | 326.54 Thousand | 257.8 Thousand |
| Change in working capital | -726.42 Thousand | 390.34 Thousand | - | -424.07 Thousand | -684.05 Thousand | - |
| Other non-cash items | 1.54 Million | -585.33 Thousand | -530.05 Thousand | 2.23 Million | 1.57 Million | -2.36 Million |
| Investing Cash Flow | - | - | - | -16.16 Million | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | 6.72 Million | 6.72 Million | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -317.82 Thousand | - |
| Common Stock Issuance | - | - | - | 6.72 Million | 6.72 Million | - |
| Other Financing Activities | - | - | - | 6.72 Million | 317.82 Thousand | - |
| Accounts receivables | 362.8 Thousand | 362.8 Thousand | - | -356.39 Thousand | -356.39 Thousand | - |
| Accounts payables | -1.11 Million | - | - | - | -259.97 Thousand | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 27.53 Thousand | 27.53 Thousand | - | -67.68 Thousand | -67.68 Thousand | - |
| Cash at beginning of period | 16.16 Million | 11.16 Million | 16.16 Million | 16.41 Million | 23.79 Million | 23.79 Million |
| Cash at end of period | 6.2 Million | 6.2 Million | 11.16 Million | 16.16 Million | 16.16 Million | 16.41 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | 146.1 Thousand | -147.47 Thousand | 38.85 Thousand | -72.3 Thousand | -111.16 Thousand |
| Net cash flow / Change in cash | -9.96 Million | -4.96 Million | -5 Million | -244.29 Thousand | -7.63 Million | -7.38 Million |
| Free Cash Flow | -9.96 Million | -5.1 Million | -4.85 Million | -7 Million | -14.28 Million | -7.27 Million |
MONET
MBH
5856
GAM
MUV2
3CP